<DOC>
	<DOCNO>NCT03051893</DOCNO>
	<brief_summary>This open label , randomise , single dose study , comprise Part A ( undertaken two separate three-period crossover cohort denote A1 A2 ) Part B ( undertaken one four-period crossover cohort ) , evaluate PK ChronocortÂ® healthy male volunteer . The washout interval Part A Part B 1-week treatment period .</brief_summary>
	<brief_title>A Two-part , Study Compare Pharmacokinetics Dose Proportionality 6 Chronocort Formulations</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Adrenal Hyperplasia , Congenital</mesh_term>
	<mesh_term>Adrenogenital Syndrome</mesh_term>
	<mesh_term>Adrenal Insufficiency</mesh_term>
	<criteria>Healthy male volunteer 18 60 year age , inclusive ( screen ) . Subjects Body Mass Index ( BMI ) 2128 . Body Mass Index = Body weight ( kg ) / ( Height ( ) ) 2 . Subjects clinically significant abnormal serum biochemistry , haematology urine examination value within 14 day prior first dose . Subjects negative urinary drug abuse screen determine within 14 day prior first dose . Subjects negative HIV Hepatitis B C result . Subjects clinically significant abnormality 12lead electrocardiogram ( ECG ) determine within 14 day prior first dose . Subjects clinicallysignificant deviation outside normal range blood pressure pulse measurement . Subjects sexual partner use effective contraception method trial 3 month last dose , example : Oral contraceptive condom Intrauterine device ( IUD ) condom Diaphragm spermicide condom Subjects available complete study . Subjects satisfy medical examiner fitness participate study . Subjects provide write informed consent participate study . Subject continue meet screen inclusion criterion prior dose . Subjects clinically significant abnormal serum biochemistry , haematology urine examination value include negative urinary drug abuse screen ( include alcohol ) prior dose . A clinically significant history gastrointestinal disorder likely influence drug absorption . Receipt regular medication within 14 day prior first dose ( include high dose vitamin , dietary supplement herbal remedy ) . Receipt vaccination within 14 day prior first dose . Evidence renal , hepatic , central nervous system , respiratory , cardiovascular metabolic dysfunction . Presence clinically significant infection ( systemic fungal viral infection , acute bacterial infection ) Current previous history tuberculosis A clinically significant history previous allergy / sensitivity Hydrocortisone and/or Dexamethasone . A clinically significant history family history psychiatric disorders/illnesses . A clinically significant history drug alcohol abuse . Inability communicate well Investigator ( i.e. , language problem , poor mental development impair cerebral function ) . Participation New Chemical Entity clinical study within previous 16 week market drug clinical study within previous 12 week . ( N.B . The washout period trial define period time elapse last dose previous study first dose next study ) Subjects consumed 2 unit alcohol per day within seven ( 7 ) day prior first dose consume alcohol within 48 hour period prior first dose . Donation 450ml blood within previous 12 week . Subjects smoke ( exsmokers smoke within 6 month prior first dose ) . Subjects work shift ( i.e . regularly alternated day , afternoon night ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>